Krónikus limfoid leukémia (CLL): vizsgálatok itt: Románia
10 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Where
- Bucharest, Cluj-Napoca, Craiova, Iași, Ovidiu
- Életkor
- 18 év and over
- People
- 249 worldwide
- Run by
- Loxo Oncology, Inc.
See details and how to joinNCT06588478 · EU 2024-515689-15-01 - No phaseTaking peopleA Real-world Study of Ibrutinib and Venetoclax (I+V) First-Line Treatment Given for Fixed-duration of Time in Participants With Chronic Lymphocytic Leukemia
- Where
- Bucharest
- Életkor
- 18 év and over
- People
- 60
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07602088 - 2. fázisTaking peopleEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Where
- Brasov, Bucharest, Iași, Ovidiu
- Életkor
- 18 év and over
- People
- 490 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04728893 · EU 2023-504931-42-00 - 3. fázisTaking peopleA Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- Where
- Brasov, Bucharest, Cluj-Napoca, Iași, Ovidiu, Timisoara
- Életkor
- 18 év and over
- People
- 386 worldwide
- Run by
- Grifols Therapeutics LLC
See details and how to joinNCT05645107 · EU 2022-502193-16-00 - 3. fázisTaking peopleA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Where
- Bucharest, Cluj-Napoca, Iași
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06973187 · EU 2025-522860-34-00 - 3. fázisTaking peopleA Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Where
- Bucharest, Cluj-Napoca
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT07277231 · EU 2025-524366-21-00 - 1. fázisTaking peopleDose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
- Where
- Bucharest, Cluj-Napoca
- Életkor
- 18 év and over
- People
- 85 worldwide
- Run by
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
See details and how to joinNCT06980116 · EU 2024-516869-36-00 - 3. fázisTaking peopleGlobal Trial in APG2575 for Patients With CLL/SLL
- Where
- Bucharest, Cluj-Napoca, Timisoara
- Életkor
- 18 év to 99 év
- People
- 400 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT06104566 · EU 2023-508005-24-00 - 1. fázisTaking peopleStudy of SGR-1505 in Mature B-Cell Neoplasms
- Where
- Bucharest, Cluj-Napoca
- Életkor
- 18 év and over
- People
- 98 worldwide
- Run by
- Schrödinger, Inc.
See details and how to joinNCT05544019 · EU 2023-505204-34-00 - 2. fázisTaking peopleStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- Where
- Bucharest
- Életkor
- 18 év and over
- People
- 75 worldwide
- Run by
- AbbVie
See details and how to joinNCT04895436 · EU 2023-504599-10-00